Design, Synthesis, and Functional Activity of Labeled CD1d Glycolipid Agonists

Invariant natural killer T cells (iNKT cells) are restricted by CD1d molecules and activated upon CD1d-mediated presentation of glycolipids to T cell receptors (TCRs) located on the surface of the cell. Because the cytokine response profile is governed by the structure of the glycolipid, we sought a method for labeling various glycolipids to study their in vivo behavior. The prototypical CD1d agonist, α-galactosyl ceramide (α-GalCer) 1, instigates a powerful immune response and the generation of a wide range of cytokines when it is presented to iNKT cell TCRs by CD1d molecules. Analysis of crystal structures of the TCR−α-GalCer–CD1d ternary complex identified the α-methylene unit in the fatty acid side chain, and more specifically the pro-S hydrogen at this position, as a site for incorporating a label. We postulated that modifying the glycolipid in this way would exert a minimal impact on the TCR–glycolipid–CD1d ternary complex, allowing the labeled molecule to function as a good mimic for the CD1d agonist under investigation. To test this hypothesis, the synthesis of a biotinylated version of the CD1d agonist threitol ceramide (ThrCer) was targeted. Both diastereoisomers, epimeric at the label tethering site, were prepared, and functional experiments confirmed the importance of substituting the pro-S, and not the pro-R, hydrogen with the label for optimal activity. Significantly, functional experiments revealed that biotinylated ThrCer (S)-10 displayed behavior comparable to that of ThrCer 5 itself and also confirmed that the biotin residue is available for streptavidin and antibiotin antibody recognition. A second CD1d agonist, namely α-GalCer C20:2 4, was modified in a similar way, this time with a fluorescent label. The labeled α-GalCer C20:2 analogue (11) again displayed functional behavior comparable to that of its unlabeled substrate, supporting the notion that the α-methylene unit in the fatty acid amide chain should be a suitable site for attaching a label to a range of CD1d agonists. The flexibility of the synthetic strategy, and late-stage incorporation of the label, opens up the possibility of using this labeling approach to study the in vivo behavior of a wide range of CD1d agonists.

[1]  K. Sakimura,et al.  of NKT cells , 2015 .

[2]  G. Besra,et al.  Amide Analogues of CD1d Agonists Modulate iNKT-Cell-Mediated Cytokine Production , 2012, ACS chemical biology.

[3]  G. Besra,et al.  Invariant natural killer T cells recognize lipid self-antigen induced by microbial danger signals , 2011, Nature Immunology.

[4]  S. van Calenbergh,et al.  Galactose‐modified iNKT cell agonists stabilized by an induced fit of CD1d prevent tumour metastasis , 2011, The EMBO journal.

[5]  M. Dauchez,et al.  The stimulating adventure of KRN 7000. , 2011, Organic & biomolecular chemistry.

[6]  G. Besra,et al.  Synthesis of a Versatile Building Block for the Preparation of 6-N-Derivatized α-Galactosyl Ceramides: Rapid Access to Biologically Active Glycolipids , 2010, The Journal of organic chemistry.

[7]  M. Venkataswamy,et al.  Lipid and glycolipid antigens of CD1d-restricted natural killer T cells. , 2010, Seminars in immunology.

[8]  M. Brenner,et al.  How invariant natural killer T cells respond to infection by recognizing microbial or endogenous lipid antigens. , 2010, Seminars in immunology.

[9]  D. Godfrey,et al.  Raising the NKT cell family , 2010, Nature Immunology.

[10]  S. Porcelli,et al.  An α‐galactosylceramide C20:2 N‐acyl variant enhances anti‐inflammatory and regulatory T cell‐independent responses that prevent type 1 diabetes , 2009, Clinical and experimental immunology.

[11]  N. Nagarajan,et al.  Mechanisms for Glycolipid Antigen-Driven Cytokine Polarization by Vα14i NKT Cells , 2009, The Journal of Immunology.

[12]  P. Wang,et al.  Facile synthesis of biotin-labelled α-galactosylceramide as antigen for invariant natural killer T cells , 2009 .

[13]  G. Besra,et al.  Incorporation of NKT Cell-Activating Glycolipids Enhances Immunogenicity and Vaccine Efficacy of Mycobacterium bovis Bacillus Calmette-Guérin1 , 2009, The Journal of Immunology.

[14]  J. Berzofsky,et al.  The contrasting roles of NKT cells in tumor immunity. , 2009, Current molecular medicine.

[15]  P. Cresswell,et al.  Kinetics and Cellular Site of Glycolipid Loading Control the Outcome of Natural Killer T Cell Activation , 2009, Immunity.

[16]  G. Besra,et al.  Synthesis of threitol ceramide and [14C]threitol ceramide, non-glycosidic analogues of the potent CD1d antigen α-galactosyl ceramide , 2009 .

[17]  V. Cerundolo,et al.  Nonglycosidic Agonists of Invariant NKT Cells for Use as Vaccine Adjuvants , 2009, ChemMedChem.

[18]  Lan Wu,et al.  Natural killer T cells and autoimmune disease. , 2009, Current molecular medicine.

[19]  S. van Calenbergh,et al.  6'-derivatised alpha-GalCer analogues capable of inducing strong CD1d-mediated Th1-biased NKT cell responses in mice. , 2008, Journal of the American Chemical Society.

[20]  T. Yamamura,et al.  Synthetic glycolipid ligands for human iNKT cells as potential therapeutic agents for immunotherapy. , 2008, Current medicinal chemistry.

[21]  G. Besra,et al.  Cutting Edge: Nonglycosidic CD1d Lipid Ligands Activate Human and Murine Invariant NKT Cells1 , 2008, The Journal of Immunology.

[22]  R. De Francesco,et al.  A novel series of potent and selective ketone histone deacetylase inhibitors with antitumor activity in vivo. , 2008, Journal of medicinal chemistry.

[23]  E. Goddard-Borger,et al.  An Efficient, Inexpensive, and Shelf‐Stable Diazotransfer Reagent: Imidazole‐1‐sulfonyl Azide Hydrochloride. , 2008 .

[24]  Anneliese O. Speak,et al.  Modulation of human natural killer T cell ligands on TLR-mediated antigen-presenting cell activation , 2007, Proceedings of the National Academy of Sciences.

[25]  J. Berzofsky,et al.  NKT cells in immunoregulation of tumor immunity: a new immunoregulatory axis. , 2007, Trends in immunology.

[26]  Natalie A. Borg,et al.  CD1d–lipid-antigen recognition by the semi-invariant NKT T-cell receptor , 2007, Nature.

[27]  M. Kronenberg,et al.  The unique role of natural killer T cells in the response to microorganisms , 2007, Nature Reviews Microbiology.

[28]  G. Besra,et al.  The length of lipids bound to human CD1d molecules modulates the affinity of NKT cell TCR and the threshold of NKT cell activation , 2007, The Journal of experimental medicine.

[29]  Gary J. Jones.  A unique role? , 2007, Emergency nurse : the journal of the RCN Accident and Emergency Nursing Association.

[30]  G. Denardo,et al.  Construction of di-scFv through a trivalent alkyne-azide 1,3-dipolar cycloaddition. , 2007, Chemical communications.

[31]  T. Yamamura,et al.  Preferential T(h)2 polarization by OCH is supported by incompetent NKT cell induction of CD40L and following production of inflammatory cytokines by bystander cells in vivo. , 2005, International immunology.

[32]  Francesco M Veronese,et al.  PEGylation, successful approach to drug delivery. , 2005, Drug discovery today.

[33]  G. Besra,et al.  Expansion and Hyperactivity of CD1d-Restricted NKT Cells during the Progression of Systemic Lupus Erythematosus in (New Zealand Black × New Zealand White)F1 Mice1 , 2005, The Journal of Immunology.

[34]  G. Besra,et al.  Modulation of CD1d-restricted NKT cell responses by using N-acyl variants of alpha-galactosylceramides. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[35]  Seokmann Hong,et al.  Lipid rafts are required for efficient signal transduction by CD1d. , 2005, Biochemical and biophysical research communications.

[36]  M. Tsuji,et al.  The C-glycoside analogue of the immunostimulant alpha-galactosylceramide (KRN7000): synthesis and striking enhancement of activity. , 2004, Angewandte Chemie.

[37]  R. DesJarlais,et al.  A novel series of potent and selective small molecule inhibitors of the complement component C1s. , 2004, Bioorganic & medicinal chemistry letters.

[38]  T. Yamamura,et al.  The clinical implication and molecular mechanism of preferential IL-4 production by modified glycolipid-stimulated NKT cells. , 2004, The Journal of clinical investigation.

[39]  D. Ly,et al.  Interleukin-4 but not interleukin-10 protects against spontaneous and recurrent type 1 diabetes by activated CD1d-restricted invariant natural killer T-cells. , 2004, Diabetes.

[40]  L. Kaer,et al.  NKT cells: what's in a name? , 2004, Nature Reviews Immunology.

[41]  M. Tsuji,et al.  Superior Protection against Malaria and Melanoma Metastases by a C-glycoside Analogue of the Natural Killer T Cell Ligand α-Galactosylceramide , 2003, The Journal of experimental medicine.

[42]  C. Ronet,et al.  Total Enantioselective Synthesis and In Vivo Biological Evaluation of a Novel Fluorescent BODIPY α‐Galactosylceramide , 2003, Chembiochem : a European journal of chemical biology.

[43]  荒木 学.  Th2 bias of CD4[+] natural killer T cells derived from multiple sclerosis in remission , 2003 .

[44]  Luke G Green,et al.  A stepwise huisgen cycloaddition process: copper(I)-catalyzed regioselective "ligation" of azides and terminal alkynes. , 2002, Angewandte Chemie.

[45]  P. Savage,et al.  Synthesis and NKT cell stimulating properties of fluorophore- and biotin-appended 6"-amino-6"-deoxy-galactosylceramides. , 2002, Organic letters.

[46]  T. Yamamura,et al.  A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells , 2001, Nature.

[47]  V. Cerundolo,et al.  Mature Dendritic Cells Prime Functionally Superior Melan-A-Specific CD8+ Lymphocytes as Compared with Nonprofessional APC1 , 2001, The Journal of Immunology.

[48]  M. G. Finn,et al.  Click Chemistry: Diverse Chemical Function from a Few Good Reactions. , 2001, Angewandte Chemie.

[49]  A. Kulkarni,et al.  Glycolipid antigen processing for presentation by CD1d molecules. , 2001, Science.

[50]  河野 鉄.  CD1d-restricted and TCR-mediated activation of V α14 NKT cells by glycosylceramides , 2000 .

[51]  Y. Koezuka,et al.  Synthesis of NBD-alpha-galactosylceramide and its immunologic properties. , 1999, Organic letters.

[52]  H. Iijima,et al.  Syntheses of biotinylated alpha-galactosylceramides and their effects on the immune system and CD1 molecules. , 1999, Journal of medicinal chemistry.

[53]  Hiroshi Sato,et al.  CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. , 1997, Science.

[54]  Samuel Zalipsky,et al.  Introduction to Chemistry and Biological Applications of Poly(ethylene glycol) , 1997 .

[55]  Y. Koezuka,et al.  Enhancing effects of α-, β-monoglycosylceramides on natural killer cell activity , 1996 .

[56]  O. Lantz,et al.  An invariant T cell receptor alpha chain is used by a unique subset of major histocompatibility complex class I-specific CD4+ and CD4-8- T cells in mice and humans , 1994, The Journal of experimental medicine.

[57]  I. Stroynowski.  Molecules related to class-I major histocompatibility complex antigens. , 1990, Annual review of immunology.

[58]  C. Terhorst,et al.  Isolation and characterization of a cDNA and gene coding for a fourth CD1 molecule. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[59]  U. Groth,et al.  Enantioselective Syntheses of (R)‐Amino Acids Using L‐Valine as Chiral Agent , 1981 .

[60]  U. Groth,et al.  Enantioselective Synthesis of α‐Methyl‐α‐aminocarboxylic Acids by Alkylation of the Lactim Ether of cyclo‐(L‐Ala‐L‐Ala) , 1979 .

[61]  I. Alam,et al.  3-Hydroxy-2-alkyl carboxylic acids related to mycolic acid , 1979 .